Fort Washington Investment Advisors Inc. OH Increases Stock Position in Certara, Inc. $CERT

Fort Washington Investment Advisors Inc. OH lifted its position in shares of Certara, Inc. (NASDAQ:CERT) by 17.7% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,675,543 shares of the company’s stock after buying an additional 402,720 shares during the period. Fort Washington Investment Advisors Inc. OH owned approximately 1.75% of Certara worth $15,251,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Northwestern Mutual Wealth Management Co. grew its position in Certara by 2,733.3% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock valued at $26,000 after acquiring an additional 2,870 shares during the period. Osaic Holdings Inc. grew its holdings in shares of Certara by 50.7% during the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock worth $41,000 after purchasing an additional 1,175 shares during the period. Tower Research Capital LLC TRC increased its position in Certara by 499.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock worth $69,000 after purchasing an additional 4,930 shares in the last quarter. Canada Pension Plan Investment Board acquired a new stake in Certara during the 2nd quarter worth approximately $83,000. Finally, Curated Wealth Partners LLC purchased a new position in Certara in the fourth quarter valued at approximately $89,000. 73.96% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

CERT has been the topic of a number of recent research reports. Stephens reduced their price target on shares of Certara from $10.00 to $9.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. Robert W. Baird dropped their price objective on shares of Certara from $7.00 to $6.00 and set a “neutral” rating for the company in a research report on Tuesday, May 12th. Weiss Ratings reissued a “sell (e+)” rating on shares of Certara in a research note on Friday, May 29th. Barclays reduced their target price on shares of Certara from $8.00 to $6.50 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. Finally, Morgan Stanley decreased their price target on shares of Certara from $11.00 to $10.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $8.85.

Certara Stock Performance

Certara stock opened at $5.83 on Monday. The firm has a market capitalization of $906.20 million, a PE ratio of -58.25 and a beta of 1.49. Certara, Inc. has a one year low of $4.45 and a one year high of $13.88. The stock’s 50 day moving average price is $5.58 and its 200 day moving average price is $6.92. The company has a debt-to-equity ratio of 0.28, a quick ratio of 1.88 and a current ratio of 1.88.

Certara (NASDAQ:CERT) last issued its quarterly earnings data on Monday, May 11th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by ($0.02). The firm had revenue of $106.92 million during the quarter, compared to analyst estimates of $106.13 million. Certara had a negative net margin of 3.60% and a positive return on equity of 3.52%. The firm’s revenue was up .8% compared to the same quarter last year. During the same period last year, the business earned $0.14 EPS. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. As a group, sell-side analysts expect that Certara, Inc. will post 0.24 EPS for the current fiscal year.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.